Vantage Investor Diligence · Sample Report
A next-generation abdominal aortic aneurysm (AAA) endograft with active supra-renal fixation, evaluated at Series A. A stand-in target, weighed against real, verifiable comparables.
Meridian's active supra-renal fixation is aimed at migration and loss of proximal seal, two long-term failure modes after endovascular aneurysm repair (EVAR). The company is pre-pivotal, and the record a reader will look for, multi-year durability data, does not exist yet. The closest real comparable, Endologix, shows that endograft durability questions can surface years after approval, though its AFX problem was type III endoleak, a different failure mode from the one Meridian's fixation addresses.
Endologix is the one AAA-endograft company in this set. The other four are adjacent vascular device companies, shown for acquisition context rather than as close comparables. Each outcome links to a public source.
| Company | What it is | Public record | Outcome |
|---|---|---|---|
| Endologix, Inc. | AAA endograft (AFX platform) — the closest comparable | AFX safety notice (July 2018), classified by FDA as a Class I recall · Endovascular Today | Chapter 11 · 2020 · now private |
| Vascular Solutions | Peripheral & coronary vascular devices | Formerly NASDAQ: VASC | Acquired · Teleflex 2017 (~$1B) |
| Shockwave Medical | Intravascular lithotripsy for calcified disease | Formerly NASDAQ: SWAV | Acquired · J&J 2024 ($13.1B) |
| Inari Medical | Mechanical venous thrombectomy (FlowTriever) | Formerly NASDAQ: NARI | Acquired · Stryker 2025 ($4.9B) |
| Penumbra, Inc. | Computer-assisted vacuum thrombectomy | NYSE: PEN | Acquisition agreed · Boston Scientific · Jan 2026 |
Sources: trade-press coverage of FDA's classification of the AFX safety notice, MedTech Dive on the Endologix Chapter 11, and the companies' and acquirers' own announcements, linked in each row.
The closest comparable's regulatory arc centered on type III endoleak with the AFX endograft: an FDA letter to health care providers in June 2018 and a July 2018 safety notice that FDA classified as a Class I recall. Endologix filed for Chapter 11 in 2020 and continues as a private company. Type III endoleak arises at component junctions or from graft fabric, and active supra-renal fixation does not address it. A reader would ask what Meridian's own fabric and junction durability data show, alongside its migration data.
IDE to PMA is the expected pathway for a new AAA endograft. Before a pivotal, a reader will look for bench durability testing and first-in-human imaging follow-up.
Active supra-renal fixation addresses migration. It does not address type III endoleak, so graft fabric and component-junction durability are separate questions. Freedom-to-operate around existing fixation and sealing claims is the IP question a reader will ask.
EVAR is billed under existing CPT codes 34701–34708, which describe the anatomy treated rather than the device. A new endograft used within those procedures does not need a new code.
Endograft pivotal trials are long and expensive. The question a reader will ask is how far the current raise reaches: to a durability readout, or only into pivotal enrollment.
We'll run the same read — real comparables, cited to public record — on a company you're weighing, and walk you through it. Your materials stay confidential; that's the point.
Methodology. Meridian Endovascular is a stand-in company created to show the Vantage diligence framework in full without exposing a client's confidential work; none of its specifics represent a real entity, and it carries no fabricated regulatory identifiers. Every comparable company is real, and the facts shown about them link to public sources. The Vantage Index and domain scores are illustrative, shown with illustrative credible intervals. In a full report the Vantage Index is a composite of the evidence available, not a prediction of outcome or a recommendation.